Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EBT: 2010-2025

Historic EBT for Altimmune (ALT) over the last 16 years, with Sep 2025 value amounting to -$19.0 million.

  • Altimmune's EBT rose 16.77% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.7 million, marking a year-over-year increase of 18.17%. This contributed to the annual value of -$95.1 million for FY2024, which is 7.53% down from last year.
  • Per Altimmune's latest filing, its EBT stood at -$19.0 million for Q3 2025, which was up 14.14% from -$22.1 million recorded in Q2 2025.
  • Altimmune's 5-year EBT high stood at -$14.9 million for Q1 2021, and its period low was -$33.5 million during Q3 2021.
  • Its 3-year average for EBT is -$22.3 million, with a median of -$22.1 million in 2025.
  • As far as peak fluctuations go, Altimmune's EBT plummeted by 122.59% in 2021, and later climbed by 29.24% in 2022.
  • Altimmune's EBT (Quarterly) stood at -$23.9 million in 2021, then climbed by 9.33% to -$21.7 million in 2022, then slumped by 46.08% to -$31.6 million in 2023, then climbed by 26.37% to -$23.3 million in 2024, then climbed by 16.77% to -$19.0 million in 2025.
  • Its EBT stands at -$19.0 million for Q3 2025, versus -$22.1 million for Q2 2025 and -$20.3 million for Q1 2025.